6-K

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

450, 5th Street

Washington, D.C. 20549

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of March, 2006

Daiichi Sankyo Company, Limited

(Translation of registrant’s name into English)

5-1, Nihonbashi 3-chome

Chuo-ku, Tokyo 103-8426

Japan

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  þ            Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  ¨            No  þ

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  ¨            No  þ

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨            No  þ

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DAIICHI SANKYO COMPANY, LIMITED
DATE: March 28, 2006	By:	/s/ Takashi Shoda
	Name:	Takashi Shoda
	Title:	President and Representative Director

EXHIBIT INDEX

Exhibit Number		Description of Exhibit
99.1	—	Press Release: “Announcement of the First Daiichi Sankyo Group R&D Meeting”

EX-99.1

Exhibit 99.1

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Takashi Shoda, President and Representative Director

(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,

Corporate Communications Department

Telephone: +81-3-6225-1126

March 28, 2006

Announcement of the First DAIICHI SANKYO Group R&D Meeting

DAIICHI SANKYO COMPANY, LIMITED would like to welcome members of the press, analysts and investors to attend its first Group R&D meeting to be held from 1:30 today. The agenda to be covered at this meeting has been outlined below.

Schedule

First Session (1:30–2:20)

1. Unification of R&D Management

GEMRAD (Global Executive Meeting of Research and Development) was established on the occasion of DAIICHI SANKYO COMPANY, LIMITED’s founding on September 28, 2005. GEMRAD is the R&D decision-making body for DAIICHI SANKYO Group’s global research and development and is comprised of members from the R&D and Marketing in Japan, America, and Europe. Since then, we have been proceeding with the unification of Sankyo and Daiichi Pharmaceutical’s R&D management.

2. Order of R&D Project Priority

During discussions focusing on GEMRAD, DAIICHI SANKYO Group selected the following five priority projects toward which it will allocate its management resources in the future.

1) CS-747 (antiplatelet agent: phase 3 in America and Europe; phase 1 in Japan)

2) DU-176b (anticoagulant agent: phase 2 in America, Europe, and Japan)

3) CS-8663 (antihypertensive agent, Olmesartan/Amlodipine combination drug: phase 3 in America and Europe)

4) DJ-927 (cancer chemotherapy agent: phase 2 in America and Europe; phase 1 in Japan)

5) DZ-697b (antiplatelet agent: phase 1 in America and Europe; preparation for phase 1 in Japan)

3. Question and Answer Session

Second Session (2:30–4:00)

1. Present Status of R&D Projects

We shall explain the present status of 16 projects, including the five priority projects. As significant progress has been made with respect to the following two projects, the following explanation has been provided.

1) CS-011 (glitazone type antidiabetic agent: phase 2 completed in America and Europe)

In latter phase 2 tests, dosage-dependent blood glucose improvement and lipid metabolism improvement superior to pioglitazone was confirmed.

2) WelChol DM (expansion of the application of anticholesteremic agent WelChol, only sold in America, toward the treatment of diabetes. Phase 3 in America)

In a portion of phase 3 tests currently being implemented, the drug’s hypoglycemic action was clearly confirmed. Application for approval is scheduled in the fourth quarter of 2006.

2. Question and Answer Session